Stock Chart

NVAX

$8.09 -4.26%
Score: 38.0 SELL
LEAPs: SELL $13
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $13
Premium: $2.09
Expiry: Jan 15, 2027
Target: $14
Score: -39

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $8.77 - $8.83 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.70
Vol: 0.98x (vs SPY: 1.0x | vs QQQ: 1.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About NVAX - Novavax Inc

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business …

Key Statistics

Market Cap $1B
P/E Ratio 3.28

This NVAX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track NVAX's price movements with trendlines, gamma walls, and key support/resistance levels.